Table 1.
Clinical characteristics of 20 patients with locally advanced NPC
| Numbers | % | |
|---|---|---|
| Gender | ||
| Male | 15 | 75.0 |
| Female | 5 | 25.0 |
| Age (years) | ||
| Median | 45.5 | |
| Range | 14–67 | |
| World Health Organization pathological type | ||
| 1 | 1 | 5.0 |
| 2 | 18 | 90.0 |
| 3 | 1 | 5.0 |
| T stage | ||
| 1 | 2 | 10.0 |
| 2 | 7 | 35.0 |
| 3 | 6 | 30.0 |
| 4 | 5 | 25.0 |
| N stage | 40.0 | |
| 1 | 1 | 5.0 |
| 2 | 16 | 80.0 |
| 3 | 3 | 15.0 |
| AJCC/UICC stage | ||
| III | 12 | 60.0 |
| IVA | 5 | 25.0 |
| IVB | 3 | 15.0 |
| Chemotherapy | ||
| Concurrent | 13 | 65.0 |
| Sequential | 7 | 35.0 |
| Concurrent drugs | ||
| CDDP+5-FU | 7 (2)* | 53.8 |
| Weekly CDDP | 5 (5)* | 38.5 |
| Weekly cetuximab | 1 (7)* | 7.7 |
| Sequential drugs | ||
| CDDP+5-FU | 5 (2)* | 71.4 |
| Docetaxel+CDDP | 2 (2)* | 28.6 |
| Median days between pCT and 1st fraction | 9.5 (3–19)† |
Notes:
*
The numbers in parentheses show the median cycles or infusions of drug delivery;
†
the numbers in parentheses show the range.
Abbreviations: NPC, nasopharyngeal carcinoma; AJCC/UICC, American Joint Cancer Committee/Union for International Cancer Control; CDDP, cisplatin; 5-FU, 5-fuorouracil; pCT, planning computed tomography.